Piper Sandler Maintains Overweight on Axsome Therapeutics, Lowers Price Target to $238
Benzinga Newsdesk 5 days ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst David Amsellem maintains Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and lowers the price target from $258 to $238.
Piper Sandler analyst David Amsellem maintains Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and lowers the price target from $258 to $238.